SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

Overview

RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.

Full Title of Study: “Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Primary Purpose: Treatment
  • Study Primary Completion Date: September 2005

Detailed Description

OBJECTIVES: – Determine the qualitative and quantitative toxicity of SCH 66336 in children with recurrent or progressive brain tumors. – Estimate the maximum tolerated dose of this drug in these patients. – Describe the pharmacokinetics of this drug with and without dexamethasone in these patients. – Investigate the efficacy of this drug in these patients. OUTLINE: This is a dose-escalation study. Patients receive oral SCH 66336 twice daily. Treatment repeats every 4 weeks for a total of 26 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of SCH 66336 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which it is predicted that 20% of patients may experience dose-limiting toxicity. An additional 6 patients are treated at the determined MTD. Patients are followed within 30 days of the last administration of the study drug and then for up to 3 months. PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.

Interventions

  • Drug: lonafarnib

Clinical Trial Outcome Measures

Primary Measures

  • Toxicities of SCH 66336 in children and adolescents with refractory CNS cancers
  • Maximum tolerated dose of SCH 66336
    • Time Frame: Four weeks
  • Pharmacokinetics of SCH 66336

Secondary Measures

  • Tumor response to SCH 66336

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Histologically confirmed recurrent or progressive (refractory) brain tumors – Histologic confirmation waived for brainstem gliomas – Bone marrow involvement allowed if transfusion independent PATIENT CHARACTERISTICS: Age: – 21 and under Performance status: – Lansky 60-100% OR – Karnofsky 60-100% Life expectancy: – More than 8 weeks Hematopoietic: – See Disease Characteristics – Absolute neutrophil count greater than 1,000/mm^3 – Platelet count greater than 75,000/mm^3 – Hemoglobin greater than 9 g/dL Hepatic: – Bilirubin no greater than upper limit of normal – SGPT and SGOT less than 2.5 times normal – Albumin greater than 3 g/dL – PT/PTT no greater than 120% upper limit of normal – No overt hepatic disease Renal: – Creatinine no greater than 1.5 times normal OR – Glomerular filtration rate greater than 70 mL/min – No overt renal disease Cardiovascular: – No overt cardiac disease Pulmonary: – No overt pulmonary disease Other: – Neurologic deficits allowed if stable for at least 1 week prior to study – More than 3rd percentile weight for height – Able to swallow pills – No uncontrolled infection – No known or suspected allergy to poloxamer 188, croscarmellose sodium, silicon dioxide, or magnesium stearate I – Not pregnant or nursing – Negative pregnancy test – Fertile patients must use effective contraception during and for up to 10 weeks after study PRIOR CONCURRENT THERAPY: Biologic therapy: – More than 6 months since prior bone marrow transplantation – More than 1 week since prior growth factors Chemotherapy: – At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered Endocrine therapy: – Concurrent dexamethasone allowed if on stable dose for at least 1 week prior to study – Concurrent oral contraceptives or other hormonal contraceptive methods allowed Radiotherapy: – More than 6 weeks since prior substantial bone marrow radiotherapy – More than 3 months since prior craniospinal radiotherapy (more than 24 Gy) or total body irradiation – More than 2 weeks since prior focal radiotherapy for symptomatic metastatic sites Surgery: – Not specified Other: – No concurrent enzyme-inducing anticonvulsant drugs – No other concurrent anticancer or experimental drug therapy

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 21 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pediatric Brain Tumor Consortium
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • James M. Boyett/PBTC Operations and Biostatistics Center Executive Director, Pediatric Brain Tumor Consortium
  • Overall Official(s)
    • Mark W. Kieran, MD, PhD, Study Chair, Dana-Farber Cancer Institute

Citations Reporting on Results

Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20;25(21):3137-43. doi: 10.1200/JCO.2006.09.4243.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.